Shandong Boyuan Pharmaceutical & Chemical Co., Ltd. (SZSE:301617) Looks Inexpensive But Perhaps Not Attractive Enough

When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 39x, you may consider Shandong Boyuan Pharmaceutical & Chemical Co., Ltd. (SZSE:301617) as an attractive investment with its 24.5x P/E ratio. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/E.

Shandong Boyuan Pharmaceutical & Chemical has been doing a good job lately as it's been growing earnings at a solid pace. It might be that many expect the respectable earnings performance to degrade substantially, which has repressed the P/E. If that doesn't eventuate, then existing shareholders have reason to be optimistic about the future direction of the share price.

View our latest analysis for Shandong Boyuan Pharmaceutical & Chemical

We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our free report on Shandong Boyuan Pharmaceutical & Chemical's earnings, revenue and cash flow.

Is There Any Growth For Shandong Boyuan Pharmaceutical & Chemical?

There's an inherent assumption that a company should underperform the market for P/E ratios like Shandong Boyuan Pharmaceutical & Chemical's to be considered reasonable.

Taking a look back first, we see that the company grew earnings per share by an impressive 16% last year. The strong recent performance means it was also able to grow EPS by 46% in total over the last three years. Accordingly, shareholders would have probably welcomed those medium-term rates of earnings growth.

Comparing that to the market, which is predicted to deliver 37% growth in the next 12 months, the company's momentum is weaker based on recent medium-term annualised earnings results.

With this information, we can see why Shandong Boyuan Pharmaceutical & Chemical is trading at a P/E lower than the market. It seems most investors are expecting to see the recent limited growth rates continue into the future and are only willing to pay a reduced amount for the stock.

What We Can Learn From Shandong Boyuan Pharmaceutical & Chemical's P/E?

Typically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

We've established that Shandong Boyuan Pharmaceutical & Chemical maintains its low P/E on the weakness of its recent three-year growth being lower than the wider market forecast, as expected. At this stage investors feel the potential for an improvement in earnings isn't great enough to justify a higher P/E ratio. Unless the recent medium-term conditions improve, they will continue to form a barrier for the share price around these levels.

The company's balance sheet is another key area for risk analysis. Our free balance sheet analysis for Shandong Boyuan Pharmaceutical & Chemical with six simple checks will allow you to discover any risks that could be an issue.

You might be able to find a better investment than Shandong Boyuan Pharmaceutical & Chemical. If you want a selection of possible candidates, check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.